Show simple item record

dc.contributor.authorHsieh, Yu-Hsiang
dc.contributor.authorDugas, Andrea F
dc.contributor.authorLoVecchio, Frank
dc.contributor.authorMcBryde, Breana
dc.contributor.authorRicketts, Erin P
dc.contributor.authorSaliba-Shaw, Kathryn
dc.contributor.authorRothman, Richard E
dc.date.accessioned2021-01-09T02:53:58Z
dc.date.available2021-01-09T02:53:58Z
dc.date.issued2020-10-02
dc.identifier.citationHsieh, Y. H., Dugas, A. F., LoVecchio, F., McBryde, B., Ricketts, E. P., Saliba‐Shaw, K., & Rothman, R. E. (2021). Intravenous peramivir vs oral oseltamivir in high‐risk emergency department patients with influenza: Results from a pilot randomized controlled study. Influenza and Other Respiratory Viruses, 15(1), 121-131.en_US
dc.identifier.issn1750-2640
dc.identifier.pmid33006445
dc.identifier.doi10.1111/irv.12794
dc.identifier.urihttp://hdl.handle.net/10150/650694
dc.description.abstractBackground Peramivir offers a single-dose intravenous (IV) treatment option for influenza (vs 5-day oral dosing for oseltamivir). We sought to compare outcomes of emergency department (ED) patients at high risk for influenza complications treated with IV peramivir vs oral oseltamivir. Methods During the 2015-16 and 2016-17 influenza seasons, adult patients in two US EDs were randomized to either oral oseltamivir or IV peramivir treatment group. Eligibility included positive molecular influenza test; met CDC criteria for antiviral treatment; able to provide informed consent and agree to follow-up assessment. Outcomes were measured by clinical end-point indicators, including FLU-PRO Score, Ordinal Scale, Patient Global Impression on Severity Score, and Karnofsky Performance Scale for 14 days. Non-inferiorttest was performed to assess comparative outcomes between the two groups. Results Five hundred and seventy-five (68%) of 847 influenza-positive patients were approached. Two hundred and eighty-four met enrollment criteria and 179 were enrolled; of these 95 (53%) were randomized to peramivir, and 84 to oseltamivir. Average FLU-PRO score at baseline was similar (peramivir: 2.67 vs oseltamivir: 2.52); the score decreased over time for both groups (day 5: peramivir: 1.71 vs oseltamivir: 1.62; day 10: peramivir: 1.48 vs oseltamivir: 1.37; day 14: peramivir: 1.40 vs oseltamivir: 1.33; allP < .05 for significantly non-inferior). Influenza-related complications were similar between two groups (All: peramivir: 31% vs oseltamivir: 21%,P > .05; pneumonia: peramivir: 11% vs oseltamivir: 14%,P > .05). Conclusions Clinical outcomes of influenza-infected patients treated with single-dose IV peramivir were comparable to those treated with oral oseltamivir, suggesting potential utility of peramivir for influenza-infected patients in the ED.en_US
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.rights© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.subjectinfluenzaen_US
dc.subjectoseltamiviren_US
dc.subjectperamiviren_US
dc.subjectemergency departmenten_US
dc.titleIntravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled studyen_US
dc.typeArticleen_US
dc.identifier.eissn1750-2659
dc.contributor.departmentUniv Arizona, Coll Med, Dept Emergency Meden_US
dc.identifier.journalINFLUENZA AND OTHER RESPIRATORY VIRUSESen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleInfluenza and other respiratory viruses
dc.source.volume15
dc.source.issue1
dc.source.beginpage121
dc.source.endpage131
refterms.dateFOA2021-01-09T02:54:12Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
irv.12794.pdf
Size:
464.4Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.
Except where otherwise noted, this item's license is described as © 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.